Program – BANFF, CANADA

Program outline subject to change. To optimize your viewing experience, please rotate your phone horizontally.

Saturday, September 14

Time	Program Outline
	IATDMCT Council Meeting

Sunday, September 15

Time	Program Outline
0800-1000	Meeting with Scientific Committee and Regional Section Chairs/Co-Chairs
1000-1500	Pre-Congress Symposium: New Frontiers in Clinical Toxicology
1600-1730	Opening Ceremony Keynote Speaker
1730-1930	Welcome Reception in the Exhibit Hall
1930	Free Evening

1000-1500 Pre-Congress Symposium: New Frontiers in Clinical Toxicology

1000-1005	Welcome
1005-1050	Leveraging a Wastewater-based Surveillance Network for SARS-CoV-2 to Understand Population Patterns of Substance Use Michael D. Parkins, University of Calgary, Canada At the end of this session participants will be able to: List the breadth of agents that can be monitored through Wastewater-based surveillance. Explain the role of WBS at a different range of scales across populations. Discuss additional metadata to include with WBS to provide granular surveillance of substance use, and toxicities across populations.
1050-1105	Refreshment Break
1105-1150	Drug Checking Services Cristiana Stefan, Centre for Addiction and Mental Health, Canada
1150-1230	Lunch
1230-1315	Use of Artificial Intelligence (AI) to Predict and Identify Novel Illicit Drugs David Wishart, University of Alberta, Canada
1315-1330	Refreshment Break
1330-1415	Public Health and Safety Impacts of Cannabis Legalization in Canada Shea Wood, Canadian Centre on Substance Use and Addiction, Canada At the end of this session participants will be able to: Describe the key components and objectives of the Cannabis Act in Canada. Identify the impacts of cannabis legalization and various regulations on public health and safety, including observed benefits and potential areas of concern. Summarize remaining knowledge gaps and outline future priorities in cannabis-related policy development, research, prevention strategies, and public education efforts. This session will provide an overview of the Cannabis Act and Canada’s progress towards its public health and safety objectives. It will address the evolving legal cannabis market and the impacts of legalization and regulations on cannabis use among people in Canada. This will be followed by a discussion on the observed benefits of cannabis legalization in Canada and some areas of concern. Finally, future priorities in policy development, research, prevention, and public education will be addressed.
1415-1500	Semi-synthetic and Hemp-derived Cannabinoids: An Activity Perspective Christophe Stove, Ghent University, Belgium At the end of this session participants will be able to: Discuss the problem of semi-synthetic and hemp-derived cannabinoids. Explain how activity-based assessment may allow to prioritize substances of higher concern. Summarize remaining knowledge gaps and outline future priorities. This lecture will provide an overview of how semi-synthetic and hemp-derived cannabinoids evolved, and why they may pose a legislative, analytical and potential health issue. It will explain how pharmacological assessment of the cannabinoid receptor (1 (CB1) activation potential may allow prioritization of those compounds that pose the highest risk, and will describe how end products containing these substances can be characterized based on composition and CB1 activity.

Monday, September 16

Time	Program Outline
0715-0815	Breakfast Roundtables R1601: Gut microbiome in individual variability to drug response R1602: The controversy on statin health outcomes: a gap between fundamental science and clinical evidence R1603: How will disposable drug sensors change the TDM landscape? R1604: Challenges of High-Resolution Mass Spectrometry for Drug Testing R1605: TDM of biologics in oncology: is there room for personalized dosing for anti-body drug conjugates R1606: Research integrity in TDM and CT
0830-0930	Plenary Presentation: Promise of Psychedelics
0930-1000	Refreshment Break in the Exhibit Hall
1000-1130	Symposium: Alternative Sampling Strategies	Symposium: Anti-Infective Drugs	Symposium: TDM of Biologics
1130-1300	Lunch	Industry Workshop with Thermo Fisher Scientific (Topic TBA)
1300-1430	Oral Presentations
1430-1600	Refreshment Break & Poster Viewing
1600-1730	Symposium: Pharmacogenetics	Symposium: TDM in Oncology	Symposium: Young Scientists Symposium
1730-1900	IATDMCT Annual General Meeting and Award Presentations: C.E. Pippenger Award Victor Armstrong Young Investigator Award Patsalos Award
1900-2030	Cocktail Reception

0715-0815 Breakfast Roundtables R1601: Gut microbiome in individual variability to drug response Roland Lawson, University of Limoges, France At the end of this session participants will be able to:

Explain the bidirectional interaction between drugs and the gut microbiome.
Discuss the impact of the gut microbiome in response to immunosuppressants.
Discuss potential strategies in the road to precision medicine by targeting the gut microbiome.

The gut microbiome has emerged as a potent drug metabolism ‘organ’, capable of the same type of reactions as the liver or other metabolic organs. The gut microbiome can activate or inactivate drugs, induce toxicity or inefficacy in the host, and influence the pharmacokinetic profile of drugs. The translation of microbiome research into impactful clinical applications for patients requires a robust and structured approach that could help build mechanistic and predictive pharmacokinetic models and develop reliable efficacy and safety models. This session will discuss the contribution of gut microbiome studies to improve TDM of immunosuppressive drugs and explore the gut microbiome as a new frontier in TDM and toxicology. R1602: The controversy on statin health outcomes: a gap between fundamental science and clinical evidence Hundie Tesfaye, Charles University and Motol University Hospital, Czech Republic At the end of this session participants will be able to:

Discuss the current controversy on statin health outcomes.

A generally declared belief is that cholesterol concentrations should be kept low to reduce the risk of cardiovascular diseases. However, studies of the relation between serum cholesterol and all-cause mortality in people on statins treatment have shown contrasting results. Some studies failed to show benefits of too low cholesterol casting doubt on the scientific justification for lowering cholesterol. More importantly, patients on statins present well-defined adverse effects such as myotoxicity including rhabdomyolysis progressing to renal failure. R1603: How will disposable drug sensors change the TDM landscape? Yasuo Yoshimi, Shibaura Institute of Technology, Japan At the end of this session participants will be able to:

Explain the principle of this molecularly imprinted sensor.
List the characteristics of this sensor.
Discuss how the use of this sensor will change the TDM field.
Describe the form of the sensor that is easy to use in the field.
Discuss further development strategies.

The research team of the chair is developing disposable sensors that can measure serum concentrations of various high-risk drugs such as vancomycin in a few tens of seconds, which is expected to significantly reduce the time, effort, and cost of analyzing blood levels required for TDM. The chair will discuss with pharmacists and physicians how this sensor will change the flow of TDM and what specifications are needed for the sensor to be widely used. R1604: Challenges of High-Resolution Mass Spectrometry for Drug Testing Hans H. Maurer, Germany At the end of this session participants will be able to:

Explain the possibilities and limitations of HRMS for drug testing.
List the challenges should be considered when applying HRMS.
Discuss how can these challenges be overcome.

Today, high-resolution mass spectrometry (HRMS) coupled to liquid chromatography (LC), gas chromatography (GC), capillary electrophoresis (CE), or paperspray (PS) is increasingly applied for drug testing etc. It provides universality, high selectivity, specificity, sensitivity, and reproducibility. Nevertheless, some challenges have to be considered such as need of experienced staff, huge amount of data to be handled, integration and automation of several data analysis software packages, regularly updated reference libraries working on all available MS platforms, differentiation of isomers, and finally, harmonization of acceptance criteria for identification. During the roundtable, these challenges, presented by the chair and contributed by the participants, will be discussed. References Maurer HH, Drug Test Anal. 2020, 172. Maurer HH, Anal Bioanal Chem 2021, 2303. Strathmann FG et al., Clin Chem 2020, 868. Wille SM et al., Curr Pharm Des 2022, 1230. R1605: TDM of biologics in oncology: is there room for personalized dosing for anti-body drug conjugates Dirk Jan Moes, Leiden University Medical Center, Netherlands At the end of this session participants will be able to:

Explain the mechanism of action and variability in exposure of ADCs.
List the bioanalytical challenges of ADC’s.
Discuss strategies to personalize the dose in order to reduce toxicity.

Radix glycyrrhizae has a sweet and flat taste, which can tonify the spleen and Chi, clear heat and detoxify, dispel phlegm and cough, and harmonize various medicines. It is widely used in clinic. The effective ingredients for detoxification include glycyrrhizic acid, glycyrrhetinic acid and so on. The mechanism of detoxification mainly includes regulating P450 enzymes and inducing toxin metabolism, Inducing the expression and function of P-glycoprotein, reacting chemically with toxins, playing an adrenocortical hormone like role. It plays a role in reducing toxicity and increasing efficacy in traditional Chinese medicine formulas. In traditional Chinese culture, radix glycyrrhizae is indifferent to fame and fortune, adept at adjusting various medicines, and can detoxify hundreds of poisons, earning it the nickname of “National Elder”. R1606: Research integrity in TDM and CT Teun van Gelder, Leiden University Medical Center, Netherlands 0830-0930 Plenary Presentation: Promise of Psychedelics Peter Silverstone, University of Alberta, Canada At the end of this session participants will be able to:

List potential therapeutic roles for psychedelics.
Discuss potential mechanism of actions for psychedelics.
Discuss potential risks and toxicology issues for psychedelics.

This session will provide a detailed overview of the potential use of psychedelics as medications both in psychiatry and in other areas, and will provide current neuroscience updates and pathophysiology which have the potential to make these drugs of huge interest in multiple clinical areas. 1000-1130 Symposium: Microsampling Presented by the Alternative Sampling Strategies Committee Co-Chairs: Christophe Stove, Ghent University, Belgium Suzanne Parker, The University of Queensland, Australia Speakers: To convert or not to convert? Considerations and recommendations to convert capillary blood microsampling concentrations to plasma concentrations Laura Boffel, Ghent University, Belgium At the end of this session participants will be able to:

Explain the differences between capillary blood concentrations and plasma concentrations.
Make an informed decision about whether it is appropriate or desired to convert capillary blood microsampling concentrations to plasma concentrations.
Discuss how to translate or convert capillary blood microsampling concentrations to plasma concentrations.

Capillary blood microsampling, a minimally invasive technique, enables the collection of small blood volumes, making it particularly suitable for e.g., remote sampling and vulnerable populations. However, capillary blood differs from venous blood in composition, which can affect the concentrations of the envisaged analyte(s). Moreover, analytes vary in their distribution between the blood cell and plasma fractions, leading to potential differences in levels between plasma and capillary blood. Since plasma is often the standard matrix for routine analyses, this discrepancy can compromise the clinician’s interpretation of capillary blood microsampling concentrations. Hence, to ensure comparability with (i) results obtained via standard plasma assays and (ii) reference ranges established in plasma, accurate conversion to plasma concentrations might be needed, which might moreover improve the reliability and validity of the microsampling-based assays. Despite the high relevance of this topic, general considerations about whether conversion is appropriate or desired and recommendations to translate capillary blood microsampling concentrations to plasma concentrations are currently lacking. Therefore, our aim is to discuss the ‘what, when and how’ of converting capillary to plasma concentrations and also provide generally applicable considerations and recommendations in this context. Continuous real-time monitoring of drugs to deliver personalised dosing Sophie Stocker, The University of Sydney, Australia At the end of this session participants will be able to:

Explain how biosensors work.
Identify therapeutic areas where biosensors have clinical utility.
Assess what additional research is required to support implementation of biosensors into practice.

By ensuring optimal dosing, therapeutic drug monitoring (TDM) improves outcomes in critically ill patients by maximizing effectiveness while minimizing toxicity. Current methods for measuring plasma drug concentrations, however, can be challenging, time-consuming, and slow to return an answer, limiting the extent to which TDM is used to optimize drug exposure. A potentially promising solution to this dilemma is provided by biosensors, molecular sensing devices that employ biorecognition elements to recognize and quantify their target molecules rapidly and in a single step. This presentation reviews the current state of the art for biosensors regarding their application to TDM, both as ex vivo point-of-care devices supporting single timepoint measurements and in vivo devices supporting continuous real-time monitoring in situ in the body. This presentation also discusses the clinical development of biosensors for TDM, including regulatory challenges and the need for standardized performance evaluation. Through precise and real-time monitoring of drugs, the application of biosensors in TDM holds great promise for enhancing the optimization of drug exposure particularly in critically ill patients, offering the potential for improved outcomes. Selected Abstract Selected Abstract 1000-1130 Symposium: The mysteries of target site concentrations of antibiotics in hard to reach infections: an evolving application of TDM? Presented by the Anti-Infective Drugs Committee Co-Chairs: Dario Cattaneo, L. Sacco University Hospital, Italy Birgit Koch, Erasmus MC, Netherlands Speakers: TDM of long-acting antibiotics for long-term use Milo Gatti, University of Bologna, Italy At the end of this session participants will be able to:

Identify the best PK/PD target for dalbavancin in the management of Staphylococcal infections.
Assess the relationship between optimal dalbavancin PK/PD target and clinical efficacy in long-term infection.
Adopt a TDM-guided strategy for optimizing dalbavancin exposure in long-term infections.

The presentation will focus on the PK/PD optimization of long-acting agents (i.e., dalbavancin and oritavancin) according to a TDM-guided strategy for the management of long-term infections. Birgit Koch, Erasmus MC, Netherlands Iris Minichmayr, Medical University of Vienna, Austria Thi Anh Nguyen, University of Sidney, Australia 1000-1130 Symposium: TDM of Biologics Presented by the TDM of Biologics Committee Co-Chairs: Dirk Jan Moes, Leiden University Medical Center, Netherlands Annick de Vries, Sanquin Diagnostic Services, Netherlands Speakers: Femke Hooijberg, Amsterdam UMC, Netherlands Zohra Layegh, Erasmus MC, Netherlands Enhancing Pediatric Care: Therapeutic Drug Monitoring of Biologic Agents in Inflammatory Diseases Ruud Verstegen, The Hospital for Sick Children, Canada At the end of this session participants will be able to:

Describe how drug metabolism of biological agents differs between children and adults.
Discuss the complexities of extrapolating target drug concentration recommendations from adults to children.
Discuss the practical considerations of therapeutic drug monitoring in children.

During this presentation, the audience will gain an understanding of how therapeutic drug monitoring of biologic agents differs between children and adults. Panel Discussion 1300-1430 Oral Presentations 1600-1730 Symposium: Genetic diversity in clinical pharmacogenomics: challenges and opportunities for NGS Presented by the Pharmacogenetics Committee Co-Chairs: Erika Cecchin, National Cancer Institute CRO Aviano, Italy Jesse Swen, Leiden University Medical Centre, Netherlands Speakers: Preventing severe fluoropyrimidine induced toxicities in the US – the impact of genetic diversity on testing decisions Daniel Hertz, University of Michigan College of Pharmacy, USA At the end of this session participants will be able to:

Describe the evidence supporting the clinical benefit of DPYD testing.
Recognize that DPYD testing is not standard of care in USA, but is becoming more common.
Explain the importance of genetic diversity in determining which variants should be included on testing panels.
Compare the benefits and drawbacks of genotyping and sequencing.

This presentation will describe the evidence supporting the clinical benefits of DPYD testing to prevent severe fluoropyrimidine toxicity. It will then explain the current status of DPYD testing in the USA, including the increase in uptake but barriers to wide-scale adoption. The presenter will then discuss the importance of genetic diversity in the USA and the benefits of using genetic testing techniques that cover the variants carried by diverse patient populations. Finally, the presentation will highlight some potential challenges with clinical implementation of comprehensive genotyping or sequencing testing strategies. The use of NGS in clinical pharmacogenomics in Psychiatry Daniel Mueller, University of Toronto, Canada Genetic diversity in pharmacogenomics research: the experience from Canada Rachel Tyndale, University of Toronto, Canada Selected Abstract 1600-1730 Symposium: Innovative ways of Therapeutic Drug Monitoring and Dose optimization in oncology Presented by the TDM in Oncology Committee Co-Chairs: Vikram Gota, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, India Dirk Jan Moes, Leiden University Medical Centre, Netherlands Speakers: Towards understanding CAR-T cell kinetics and dynamics: Optimization of clinical trials and clinical practice using modelling and simulation Fenja Klima, Freie Universität Berlin, Germany At the end of this session participants will be able to:

List the challenges for CAR-T quantification in clinical trials and clinical practice.
Explain the unique characteristics of CAR-T cells with focus on kinetics.
Discuss opportunities to optimize CAR-T cell sampling design in clinical trials and clinical practice.
Discuss challenges and strategies to bridge current knowledge gaps and improve treatment with CAR-T cells.

Chimeric antigen receptor (CAR)-T cell therapy is a novel cellular immunotherapy and has impressively improved treatment outcomes for many cancer patients. However, a substantial percentage of patients initially fails to enter remission or eventually relapses. Therefore, a better understanding of the kinetics and dynamics of CAR-T cells in a patient and of early predictors of response and survival is needed. Pharmacometric modelling and simulation is a powerful tool to integrate clinical data and mechanistic knowledge on CAR-T cell kinetics and dynamics to answer such questions. However, owing to the recent introduction into clinical practice, clinical data on CAR-T cell therapy is rare and highly heterogeneous, often hindering a meaningful evaluation. In my talk I will highlight challenges and knowledge gaps in CAR-T cell therapy. Furthermore, I will discuss strategies and opportunities to optimize and harmonize CAR-T cell sampling in the clinic to bridge these knowledge gaps and to ultimately contribute to a safe and efficacious therapy with CAR-T cell products. Quantitative circulation tumor DNA (ctDNA) measurements to guide oncological therapy Speaker TBA Selected Abstract Selected Abstract 1600-1730 Symposium: Young Scientists Symposium Presented by the Young Scientists Committee Co-Chairs: Thi Anh Nguyen, University of Sidney, Australia Lea Wagmann, Saarland University, Germany Speakers: Point-of-care molecular diagnosis and treatment to tackle global health: tuberculosis as a case study Gia-Phong Vu, Ho Chi Minh National University, Vietnam Pharmacokinetics of orphan formulations for pediatric patients Lucas Brstilo, Hospital de Pediatría Garrahan, Argentina How to investigate the toxicokinetics of new psychoactive substances? Lea Wagmann, Saarland University, Germany At the end of this session participants will be able to:

Explain the importance of NPS toxicokinetic studies.
List different models suitable to study the toxicokinetics of NPS.
Specify individual advantages and disadvantages.

The continuously increasing number of new psychoactive substances (NPS) available on the drugs of abuse market poses a challenge for clinical and forensic toxicologists. These NPS belong to various chemical classes and only very limited data concerning their safety and toxicokinetic properties are available once they appear on the market. Similar to other xenobiotics, NPS undergo absorption, distribution, metabolism, and excretion processes after consumption. Therefore, the inclusion of metabolites in mass spectral libraries is crucial, especially for urine screening purposes. Authentic human samples may represent the gold standard for identification of metabolites but are often not available and clinical studies cannot be performed due to ethical concerns. However, numerous alternative in vitro and in vivo models are available. The talk will give an overview on selected models, discuss current studies, and highlight recent developments. Biomarkers of antipsychotic-induced metabolic syndrome: Where we stand and where to head to Hualin Cai, The Second Xiangya Hospital of Central South University, China

Tuesday, September 17

Time	Program Outline
0715-0815	Breakfast Roundtables R1701: Discussion & Guide to Implementing a Successful Beta-Lactam Therapeutic Drug Monitoring Program R1702: Magical Chinese Medicine – Radix Glycyrrhizae R1703: Unsafeness of uncontrolled, so-called edible cannabinoid products containing HHC: lessons to be learned from recent incidents in Czech schoolchildren and adolescents R1704: Use of the hollow fiber infection model to generate PK-PD targets in humans R1705: Reflections on the use of the direct alcohol biomarker PEth in clinical and forensic toxicology R1706: Personalized medicine substance of use and misuse: the role of clinical laboratories
0830-0930	Plenary Presentation: Precision Medicine in Cancer Treatment
0930-1000	Refreshment Break
1000-1130	Symposium: Clinical Toxicology & Drugs of Misuse	Symposium: TDM in Oncology	Symposium: Immunosuppressive Drugs & Biomarker
1130-1300	Lunch	Industry Workshop with Shimadzu (Topic TBA)
1300-1430	Oral Presentations
1430-1530	IATDMCT Annual General Meeting
1530-1600	Refreshment Break & Poster Viewing
1600-1730	Symposium: Toxicology & Environmental Health	Symposium: Anti-Infective Drugs	Symposium: TDM of Biologics/ Pharmacometrics
1730-1830	Poster Viewing
1930-2200	Congress Dinner at Mount View Barbecue! A truly unique, western Canadian experience!

0715-0815 Breakfast Roundtables

R1701: Discussion & Guide to Implementing a Successful Beta-Lactam Therapeutic Drug Monitoring Program
Paul J. Jannetto, Ph.D., DABCC, FADLM, MT(ASCP)

At the end of this session participants will be able to:

Identify key stakeholders and champions necessary to successfully implement a TDM program.
Design a strategy to incorporate a local beta-lactam TDM program.
Summarize the results from setting up a beta-lactam TDM program.

In critically ill patients, beta-lactam antibiotics exhibit highly variable pharmacokinetics (PK) which leads to unpredictable therapeutic and toxic effects. Beta-lactam therapeutic drug monitoring (TDM) can improve precision dosing and clinical outcomes, but has not been widely implemented in most hospitals around the world. This roundtable discussion will discuss the practical considerations around implementing a beta-lactam TDM program at one medical center and the organizational infrastructure required, clinical workflows\/tools, educational strategies, and supportive materials necessary for a successful implementation. Data from adult and pediatric ICU patients will be shared from the result of this program. Participants will share and learn various ways to expand TDM programs.

R1702: Magical Chinese Medicine – Radix Glycyrrhizae
Meimei Gao, and Ning Huang

At the end of this session participants will be able to:

Explain the pharmacological and detoxification mechanism of radix glycyrrhizae.
Outline the classical prescriptions of radix glycyrrhizae.
Describe the characteristics of radix glycyrrhizae in Chinese traditional culture.
Discuss the medicinal history, growth habit, economic value and distribution of radix glycyrrhizae.

Radix glycyrrhizae has a sweet and flat taste, which can tonify the spleen and Chi, clear heat and detoxify, dispel phlegm and cough, and harmonize various medicines. It is widely used in clinic. The effective ingredients for detoxification include glycyrrhizic acid, glycyrrhetinic acid and so on. The mechanism of detoxification mainly includes regulating P450 enzymes and inducing toxin metabolism, Inducing the expression and function of P-glycoprotein, reacting chemically with toxins,playing an adrenocortical hormone like role. It plays a role in reducing toxicity and increasing efficacy in traditional Chinese medicine formulas.
In traditional Chinese culture, radix glycyrrhizae is indifferent to fame and fortune, adept at adjusting various medicines, and can detoxify hundreds of poisons, earning it the nickname of “National Elder”.

R1703: Unsafeness of uncontrolled, so-called edible cannabinoid products containing HHC: lessons to be learned from recent incidents in Czech schoolchildren and adolescents
Tesfaye Hundie,

At the end of this session participants will be able to:

Discuss the risk of substances found over the counter especially in children, where designs are attracting in this age group.
Develop early warning strategy locally.
Develop online quality analytical facilities.
Organize all stakeholders’ cooperation to prevent fatal outcomes.

Hexahydrocannabinol (HHC), is synthetic version of tetrahydrocannabinol (THC) gained by hydrogenation of parent THC. Both benefits and hazards of HHC are not well studied although unpublished incidents showed that it is not safe–enough. The legal status of HHC varies between countries across the world. This contribution is to involve discussion on the state of the art based on reported incidents in Czech Republic, leading to ban HHC since 1.3.2024 putting the country on the list of European countries banning HHC.
The outcomes of the discussion is aiming to make some kind of consensus at list within the IATDMCT society leading to disseminations of the facts further to relevant bodies to avoid the dangers following the abuse substances.

R1704: Use of the hollow fiber infection model to generate PK-PD targets in humans
Michael Neely , Gauri Rao, Joy Gibson and Jason Roberts

At the end of this session participants will be able to:

Describe the set up of a hollow fiber infection model (HFIM).
Explain how the hollow fiber can be used to determine in vitro pharmacokinetics and pharmacodynamics against a wide array of organisms.
Discuss translation of hollow fiber results to patient dosing and TDM concentration targets.

This session will cover pharmacokinetic and pharmacodynamic assessments to generate target exposures focusing on use of the in vitro hollow fiber system and translation to human dosing.

R1705: Reflections on the use of the direct alcohol biomarker PEth in clinical and forensic toxicology
Christophe Stove, Ghent University, Belgium

R1706: Personalized medicine substance of use and misuse: the role of clinical laboratories
Manuela Neuman, Ph.D., FCACB

At the end of this session participants will be able to:

Discuss the clinical and economic value of using immunogenetic markers of toxicity of therapeutics.
Describe the role the harm reduction strategies in diminishing the negative consequences of drug abuse by using the drug abuse checking services to promote toxicity awareness and protect the public.
Promote the adoption of personalized medicine concepts to benefit patients.

Personalized medicine help physicians to use diagnostic tests to determine which medical treatments will work best for each patient or what is the natural product, drug of use or abuse that produce a toxic reaction to a specific individual. By combining the data from those tests with an individual’s medical history health care providers can develop targeted treatment and prevention plans. The treatment and/or enforcement strategies do not eliminate substance misuse.
Hence several harm reduction strategies have been sought and implemented in order to diminish, the negative consequences associated with drug abuse.
Examples are methadone or suboxone maintenance program, needle exchange programs or outreach initiatives.

0830-0930 Plenary Presentation: Precision Medicine in Cancer Treatment
Melissa McConechy, McGill University Health Centre, Canada

1000-1130 Symposium: Clinical and Forensic Toxicology – Hot Topics and Substances
Presented by the Clinical Toxicology & Drugs of Misuse Committee
Co-Chairs:
Eric Franssen, Onze Lieve Vrouwe Gasthuis, Netherlands
Loralie Langman, Mayo Clinic, USA

Speakers:
Karen van den Hondel, Public Health Service of Amsterdam (GGD Amsterdam), Netherlands
Cristiana Stefan, Centre for Addiction and Mental Health, Canada

Cytotoxicity Testing of NPS in Clinical Toxicology
Lea Wagmann, Saarland University, Germany

At the end of this session participants will be able to:

Explain the importance of cytotoxicity testing.
List different strategies suitable to study the in vitro cytotoxicity of NPS.
Specify individual advantages and disadvantages.

In therapeutic drug development, in vitro cytotoxicity testing is crucial and mandatory. This is not the case for non-therapeutic compounds such as new psychoactive substances (NPS). Numerous case reports of intoxications or even deaths after intake of NPS demonstrate their threat on public health. Some reports associated their intake with liver failure, but detailed knowledge about certain cytotoxicity is usually unknown. To reveal such a potential is thus one task in the field of (analytical) toxicology. The knowledge can in turn help to explain outcomes of chronic intake, symptoms in overdose cases, or fatal events associated with NPS abuse. Recent studies investigated single cytotoxicity biomarkers in individual experiments such as cell viability, leakage of lactate dehydrogenase or cell death. To gain a deeper insight into intracellular processes, it may be favorable to monitor multiple parameters using high-content screening assays. The talk will present, summarize, and discuss published studies and strategies related to the cytotoxic potential of non-therapeutic compounds, particularly NPS.

1000-1130 Symposium: Pharmacokinetics and PGX to optimize drug therapy in Oncology
Presented by the TDM in Oncology Committee
Co-Chairs:
Vikram Gota, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, India
Dirk Jan Moes, Leiden University Medical Center, Netherlands

Speakers:
Use of modeling and simulation for the regulatory approval of a liquid formulation of 6-mercaptopurine for use in children based on a PK study in adult healthy volunteers
Vikram Gota, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, India
Selected Abstract
Selected Abstract

1000-1130 Symposium: Biomarkers in Solid Organ Transplantation: now and for years to come
Presented by the Immunosuppressive Drugs Committee
Chair:
Nuria Lloberas Blanch, IDIBELL Bellvitge Biomedical Research Institute, Spain

Speakers:
Jana Stojanova, University of New South Wales, Australia
Guido Trezeguet, Pediatric Hospital Dr. Juan P Garrahan, Argentina
Raman Venkataramanan, University of Pittsburgh, USA

1600-1730 Symposium: Toxicology & Environmental Health
Presented by the Toxicology & Environmental Health Committee
Chair:
Souleiman El Balkhi, University of Limoges, France

Speakers:
The Impact of Environmental pollution to Antimicrobial Agents on Medical Resistance
Jana Stojanova, University of New South Wales, Australia

Glyphosate: The Eternal Debate and EFSA’s Reliance on Regulatory Findings
Souleiman El Balkhi, University of Limoges, France

Per- and Polyfluoroalkyl Substances (PFAS): An Old Danger and a New Threat?
Nolwenn Noisel, University of Montreal, Canada

At the end of this session participants will be able to:

Cite the most common health effects of PFAS.
Evaluate the public health impact of PFAS exposure.
Identify vulnerable populations and determinants of exposure.
Discuss the use of biomonitoring and risk analysis strategies.

The presentation will aim to provide an overview of the most recent knowledge on PFAS. A definition and the main classifications will be presented first, followed by a mention of the primary health effects. The focus will then shift to vulnerable populations and those particularly exposed, such as children and certain workers like firefighters. Finally, PFAS biomonitoring strategies will be discussed, along with their usefulness in risk analysis and public health management.

1600-1730 Symposium: Dish of the Day
Presented by the Anti-Infective Drugs Committee
Chairs:
Sophie Stocker, University of Sydney, Australia

Speakers:
Isabel Spriet, University of Leuven, Belgium
Rekha Pai Mangalore, Monash University, Australia
Maaike Sikma, Utrecht University, Netherlands
Jana Stojanova, University of New South Wales, Australia
Yuko Shimamoto, Osaka University, Japan

1600-1730 Symposium: TDM of Biologics/ Pharmacometrics
Presented by the TDM of Biologics and Pharmacometrics Committees
Co-Chairs:
Anders Åsberg, Oslo University, Norway
Iris Minichmayr, Medical University of Vienna, Austria
Dirk Jan Moes, Leiden University Medical Center, Netherlands
Annick de Vries, Sanquin Diagnostic Services, Netherlands

Speakers:
Iris Minichmayr, Medical University of Vienna, Austria
Stephan van den Berg, Sanquin Diagnostic Services, Netherlands
Selected Abstract
Selected Abstract

Wednesday, September 18

Time	Program Outline
0730-0930	Committee Meetings
0930-1000	Refreshment Break
1000-1130	Symposium: Anti-Infective Drugs / Pharmacometrics	Symposium: TDM of Biologics/ TDM in Oncology	Symposium: Regional Asia Pacific Section Symposium
1130-1300	Lunch	Industry Workshop with HLS Therapeutics and Saladax (Topic TBA
1300-1430	Workshop: Clinical Toxicology & Drugs of Misuse	Symposium: Joint Symposium with ACCP	Symposium: Communications Committee Symposium
1430-1500	Closing Ceremony

1000-1130 Symposium: Children are not small adults: paving the road to PK/PD dose optimization of anti-infectives in children Presented by the Anti-Infective Drugs Committee Co-Chairs: Pieter de Cock, Ghent University, Belgium Iris Minichmayr, Medical University of Vienna, Austria Speakers: Pieter de Cock, Ghent University, Belgium Samuel Dubinsky, University of Waterloo, Canada Implementing model-informed precision dosing of antibiotics at Cincinnati Children’s Hospital Medical Center Sonya Tang Girdwood, Cincinnati Children’s Hospital Medical Center, USA At the end of this session participants will be able to:

Describe the beta-lactam model-informed precision dosing service at Cincinnati Children’s Hospital Medical Center.
Name some challenges in implementing an antibiotic precision dosing service.
Recognize patient scenarios that may benefit from model-informed precision dosing.

In this presentation, Dr. Tang Girdwood will describe the model-informed precision dosing service for beta-lactam antibiotics that was recently launched at Cincinnati Children’s. She will provide details of the work-flow and the challenges in launching a service. She will also provide example(s) of patients who may benefit from this service. Hybrid use of machine learning and population PK/PD to optimize anti-infectives dosing in children Wei Zhao, Shandong University, China At the end of this session participants will be able to:

Discuss the population PK and machine learning.
Describe how to combine the two methods in PK analysis.
Explain how to use the two approaches to optimize dosing in children.

Children are in a continuous and dynamically changing state of growth and development. Marked differences in the pharmacokinetic and pharmacodynamic behavior of many drugs are reported between children and adults due to the developmental changes in physiological parameters during childhood. The lack of pediatric clinical trial data directly results in the variation and uncertainty of drug therapy in pediatric clinical practice. The urgent need to improve pediatric drug therapy has been recognized by regulators and public health professionals. There has been a growing interest in exploring innovative methodology to optimize pediatric drug development. In this context, pharmacometrics presents a promising and valuable approach. Pharmacometrics is the science of quantitative pharmacology. In application to pediatrics, it involves primarily developmental pharmacokinetic and pharmacodynamic modeling and simulation, which can combine information from many diverse sources as drug characteristics, developmental clinical pharmacology, physiological changes during childhood, pediatric disease and statistics. This presentation will use cases studies to demonstrate how to apply modeling and simulation in optimization of pediatric clinical trial and personalization of drug therapy. 1000-1130 Symposium: TDM of Biologics/ TDM in Oncology Presented by the TDM of Biologics and TDM in Oncology Committees Co-Chairs: Vikram Gota, Advanced Centre for Treatment, Research & Education in Cancer (ACTREC), Tata Memorial Centre, India Dirk Jan Moes, Leiden University Medical Center, Netherlands Speakers: Model informed (precision) dosing of Antibody Drug Conjugates in (hemato)oncology Dirk Jan Moes, Leiden University Medical Center, Netherlands Selected Abstract Selected Abstract 1000-1130 Symposium: Regional Asia-Pacific Section (RAPS) Symposium Presented by the Regional Asia-Pacific Section (RAPS) Co-Chairs: Debbie Marriott, St Vincent’s Private Hospital, Australia Sumith Mathew, Christian Medical College Vellore, India Speakers: Vancomycin-Associated Acute Kidney Injury in Indonesia: A Preliminary Study Jefman Efendi Marzuki HY, Universitas Surabaya; Ubaya Hospital, Indonesia Rovina Ruslami, Hasan Sadikin Hospital, Bandung, Indonesia At the end of this session participants will be able to:

Discuss how Vancomycin is used in hospitals in Indonesia and the prevalence of vancomycin-induced acute kidney injury (AKI) among patients in Indonesia.
Outline the justification/the rationale for the establishment of TDM service in Indonesia.
Promote the rational and prudent use of medications.

The presentation will be about the intention to establish the TDM service in Indonesia, a country with almost 300 million of population and more than 3,000 hospitals. We will present the preliminary study about vancomycin used in 5 different hospitals in Indonesia, the prevalence of vancomycin-associated AKI, and the determinants. We will also describe our plan to conduct several studies to support the need for TDM service in Indonesia. Smita Pattanaik, Postgraduate Institute of Medical Education & Research (PGIMER), India Roopali Somani, Nizams Institute of Medical Sciences, India 1300-1430 Workshop: Clinical and post mortem toxicology cases: Bring your own cases Presented by the Clinical Toxicology & Drugs of Misuse Committee Co-Chairs: Eric Franssen, Onze Lieve Vrouwe Gasthuis, Netherlands Peter Zweipfenning, MVZ Labor Stein, Germany Moderators: Eric Franssen, Onze Lieve Vrouwe Gasthuis, Netherlands Daan Huntjens, Amsterdam University Medical Center, Netherlands Marieke Sturkenboom, University of Groningen, Netherlands At the end of this session participants will be able to:

Explain comprehensive toxicology screening in clinical and forensic toxicology.
List novel options for enhanced eliminations in cases of intoxications (Cytosorbent?).
Discuss unexpected findings in suspected intoxications.

1300-1430 Symposium: Joint Symposium with the American College of Clinical Pharmacology (ACCP) Chair: Michael Neely, University of Southern California, USA Speakers: Jasmine Hughes, InsightRx, USA Attendees will learn different ways models can be incorporated in the patient care process for oncology and other disease areas, and will become familiar with the strengths and limitations of PKPD versus ML models for predictions.

Neutropenia as an important case study for predicting drug-related adverse events.
Benefits and drawbacks of PKPD approaches and ML approaches for predicting clinical outcomes.
Development of a hybrid PKPD/ML model.
Evaluation of the hybrid PKPD/ML model.

Situating this approach in the broader context of how predictive models can support clinical decision-making and improve patient care. The Use, Positive and Negative, of AI in Clinical Toxicology and Pharmacology Marc Labriffe, University of Limoges, France

How machine learning (ML) can be used to estimate exposure of immunosuppressive drugs (AUCs).
How hybrid models (PopPK and ML) can improve estimation of exposure.
What are the advantages of using ML methods to improve therapeutic drug monitoring.
What are the limitations of using ML methods and how can we prevent them (big data and simulations, overfitting and external datasets…).
The utility of synthetic data for multicentric health studies (privacy, fidelity).
How it is applied in our international website in daily practice.
How it is also used to predict the a priori achievement of exposure targets for antibiotics.

1300-1430 Symposium: Future Prospects for Preventive Medicine Applying Pharmacogenomics, Metabolomics, Proteomics, and Microbiome Presented by the Communications Committee Co-Chairs: Ryuji Kato, Osaka Medical and Pharmaceutical University, Japan Miao Yan, Second Xiangya Hospital of Central South University, China Speakers: Dosing Algorithms for Tacrolimus in the Era of Next-Generation Sequencing Smita Pattanaik, Post Graduate Institute of Medical Education and Research, India Metabolomics as a promising tool for individualized healthcare Ofelia Noceti, National Center for Liver Transplantation and Liver Diseases, Uruguay At the end of this session participants will be able to:

Metabolic Profiles/¨Pathways: Describe how metabolites are the end products of cellular processes and how their levels can reflect the functional status of an individual’s metabolism, paving the way for the development of targeted therapies.
Biomarker Discovery: Discuss how metabolomics can identify biomarkers associated with specific diseases, providing insights into early diagnosis, disease progression, and treatment response.
Personalized Medicine: Explain how metabolomics can contribute to personalized healthcare by tailoring treatment strategies to an individual’s metabolic profile, optimizing drug efficacy, and minimizing adverse effects.
Nutritional Assessment: Discuss how metabolomics can be used to assess an individual’s nutritional status, identify dietary patterns, and provide personalized dietary recommendations for better health outcomes.

Metabolomics is a field of “omics” research that focuses on the systematic study of small molecule metabolites present in cells, tissues, or biofluids. It aims to identify and quantify all the metabolites in a biological sample to understand the metabolic processes and pathways involved in various physiological and pathological conditions. Metabolomics has the particularity to integrate the relationships form proteome and their upstream counterparts, as well as those coming from the environment. Metabolites can serve as signals to monitor disease development or progression. As a tool for individualized healthcare, metabolomics has the potential to revolutionize the way we approach disease diagnosis, treatment, and prevention. Microbiome and Inflammasome in Gastrointestinal Diseases Manuela Neuman, University of Toronto, Canada Damage associated molecular patterns as a predictive biomarker of drug induced liver injury Ryuji Kato, Osaka Medical and Pharmaceutical University, Japan At the end of this session participants will be able to:

Describe the mechanism of reactive metabolites formation and inflammasome activation by reactive metabolites.
Explain the inflammasome activation by DAMPs in immune cells.
Discuss the potential of DAMPs as early biomarkers of IDILI.

Idiosyncratic drug-induced liver injury (IDILI) remains a serious problem; most IDILI is immune-mediated and there is growing evidence that reactive metabolites trigger an immune response. Reactive metabolites directly or indirectly activate inflammasomes in immune cells, causing IDILI. Reactive metabolites cause cellular stress, leading to the release of damage-associated molecular patterns (DAMPs), and DAMPs activate immune cells. A comprehensive analysis is desirable, as there are many other types of DAMPs. If any of them can be used as early biomarkers, they could be applied as predictive markers for the development of IDILI. This symposium will introduce the currently reported DAMPs, including comprehensive analyses, and consider the potential of DAMPs as early biomarkers of IDILI.